Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Do polynucleotides boost collagen and elastin?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
Polynucleotides may support collagen and elastin activity by providing nucleotide building blocks and signalling through pathways linked with fibroblast activity, extracellular-matrix repair and tissue hydration. In intimate tissue, the aim is not instant volume but gradual improvement in tissue quality. Evidence is still developing, so claims should stay cautious and be linked to consultation, symptom assessment and realistic timelines.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Origin
Highly purified DNA fragments typically extracted from trout or salmon sperm, chosen for their high spectral compatibility with human DNA.
Primary Indication
Management of Genitourinary Syndrome of Menopause (GSM), vulvovaginal atrophy (VVA), and non-menopausal vaginal dryness (e.g., from contraceptives or lactation).
Key Benefits
Increases tissue hydration, stimulates neovascularization (angiogenesis), regulates water balance (homeostasis), and mitigates oxidative stress.
Key point 4
Suitability must be confirmed after consultation and assessment.
Important safety note
General Safety: PNs boast a highly favorable safety profile; because the extraction process removes all proteins, the risk of an immunogenic or allergic response is virtually zero.
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Efficacy: Real-world studies and clinical trials show substantial improvements in the Vaginal Health Index (VHI), transitioning patients from severe atrophy to mild atrophy or complete symptom clearance.
Why it happens
Breast Cancer Survivors: PNs provide a critical, evidence-based regenerative option for breast cancer survivors or those with a history of gynaecological cancer who suffer from iatrogenic menopause and are strictly.
Evidence limits
Sexual Function: The restoration of vaginal tissue architecture correlates with reported improvements in the Female Sexual Function Index (FSFI), dramatically reducing pain during sex.
Treatment fit
Formulations: The therapy is versatile and available as in-clinic injectables (PN-HPT®), daily at-home vaginal ovules (PNHA), and topical creams.
What this means in practice
Formulations: The therapy is versatile and available as in-clinic injectables (PN-HPT®), daily at-home vaginal ovules (PNHA), and topical creams.
Injectable Protocols: Treatment typically involves 3 "priming" sessions spaced 2-3 weeks apart, followed by 2 "consolidation" sessions (often combining PNs with hyaluronic acid).
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Efficacy: Real-world studies and clinical trials show substantial improvements in the Vaginal Health Index (VHI), transitioning patients from severe atrophy to mild atrophy or.
It protects safety
General Safety: PNs boast a highly favorable safety profile; because the extraction process removes all proteins, the risk of an immunogenic or allergic response.
It reviews alternatives
Formulations: The therapy is versatile and available as in-clinic injectables (PN-HPT®), daily at-home vaginal ovules (PNHA), and topical creams.
It sets expectations
Injectable Protocols: Treatment typically involves 3 "priming" sessions spaced 2-3 weeks apart, followed by 2 "consolidation" sessions (often combining PNs with hyaluronic acid).
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
Formulations: The therapy is versatile and available as in-clinic injectables (PN-HPT®), daily at-home vaginal ovules (PNHA), and topical creams.
Consultation priorities
Consultation & Assessment: The journey begins with a thorough medical history, assessment of VVA symptoms, and establishing a baseline Vaginal Health Index (VHI) to rule out active infections and confirm eligibility.
Consent
Aftercare
Follow-up
Before treatment
Consultation & Assessment: The journey begins with a thorough medical history, assessment of VVA symptoms, and establishing a baseline Vaginal Health Index (VHI) to rule out active infections.
During care
Active Treatment Phase: Patients undergo their scheduled series of in-clinic injections (using topical numbing) or complete their prescribed course of daily vaginal ovules.
Aftercare
Maintenance & Follow-Up: Routine follow-up visits evaluate symptom relief and mucosal health. Maintenance injectable sessions are often recommended every 6 to 9 months to sustain tissue regeneration.
When to reassess
If the expected response does not occur, reassessment is safer than automatic repeat treatment.
Practical expectations
Injectable Protocols: Treatment typically involves 3 "priming" sessions spaced 2-3 weeks apart, followed by 2 "consolidation" sessions (often combining PNs with hyaluronic acid).
In-Clinic Procedures: Injectable treatments are minimally invasive but can be uncomfortable; a topical anaesthetic cream is usually applied prior to the procedure to minimise pain.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Formulations: The therapy is versatile and available as in-clinic injectables (PN-HPT®), daily at-home vaginal ovules (PNHA), and topical creams.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Common Side Effects: localised treatments may cause occasional, mild, and rapidly transitory burning, itching, or discomfort that resolves spontaneously within a few hours.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 53 imported records. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, clinical trial records; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
